Yale JF, Catarig AM, Grau K, et al. - In this multicenter, prospective, observational study (SURE Canada study), researchers sought to examine once-weekly (OW) semaglutide, a glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D) in routine clinical practice. Adults with T2D and ≥ 1 documented HbA _1c value ≤ 12 weeks before semaglutide beginning were registered. Semaglutide was started on 452 patients, and 356 completed the treatment study. Patients treated with OW semaglutide in routine clinical practice in SURE Canada experienced clinically significant improvements in HbA _1c, body weight, and other outcomes, supporting the use of semaglutide in routine clinical practice.